View Post

Rare Patient Voice: Non-Small Cell Lung Cancer Patients

In Paid Opportunities For The Cancer Community by Barbara Jacoby

Study Details: 60 min Phone Interview Compensation $100 Please sign up at the link below for more information or to see if you qualify. https://rarepatientvoice.com/LetLifeHappen/ Why Sign up with Rare Patient Voice? Who knows better than you about your journey and experiences?  We connect you with researchers who are developing products and services which can help you and others with …

View Post

Rare Patient Voice: Non-Small Cell Lung Cancer Patients and Caregivers

In Paid Opportunities For The Cancer Community by Barbara Jacoby

Study Details: 135 mins Interview (includes pre-work) Compensation $225 Please sign up at the link below for more information or to see if you qualify. https://rarepatientvoice.com/LetLifeHappen/ Why Sign up with Rare Patient Voice? Who knows better than you about your journey and experiences?  We connect you with researchers who are developing products and services which can help you and others …

View Post

Rare Patient Voice: Non-Small Cell Lung Cancer Patients and Caregivers

In Paid Opportunities For The Cancer Community by Barbara Jacoby

Study Details: 60 min Web-Assisted Phone Interview Compensation $100 Please sign up at the link below for more information or to see if you qualify. https://rarepatientvoice.com/LetLifeHappen/ Why Sign up with Rare Patient Voice? Who knows better than you about your journey and experiences?  We connect you with researchers who are developing products and services which can help you and others …

View Post

Phase III trial evaluating Libtayo in NSCLC halted because of significant OS improvemen

In Clinical Trials by Barbara Jacoby

From: cancerletter.com The primary endpoint of overall survival was met in a phase III trial comparing the PD-1 inhibitor Libtayo (cemiplimab) to platinum-doublet chemotherapy in patients with first-line locally advanced or metastatic non-small cell lung cancer who tested positive for PD-L1 in ≥50% of tumor cells. Libtayo is jointly developed and commercialized by Regeneron and Sanofi under a global collaboration …

View Post

FDA Grants Priority Review to Capmatinib in METex14+ NSCLC

In Clinical Trials by Barbara Jacoby

By: Jason M. Broderick From: onclive.com The FDA has granted a priority review designation to a new drug application (NDA) for capmatinib (INC280) for use as treatment for newly diagnosed and previously treated patients with locally advanced or metastatic MET exon14 skipping (METex14)—mutated non–small cell lung cancer (NSCLC).1 The priority designation, which will expedite the review and development of capmatinib …

View Post

AstraZeneca reports promising lung cancer results from Phase III immunotherapy drug trial

In Clinical Trials by Barbara Jacoby

By: Alaric DeArment From: medcitynews.com The company said Imfinzi and chemotherapy, with or without tremelimumab, extended progression-free survival in first-line non-small cell lung cancer versus chemotherapy, setting up Imfinzi as a potential competitor to Merck’s Keytruda. Overall survival data are expected next year A British drugmaker’s program to develop an immunotherapy combination for a type lung cancer that could compete …

View Post

Inivata to Employ Liquid Biopsy Test in EORTC Phase II NSCLC Study of Lorlatinib

In Clinical Trials by Barbara Jacoby

By: Staff Reporter From: genomeweb.com Liquid biopsy firm Inivata said today that it is collaborating with the European Organization for Research and Treatment of Cancer, using its InVisionFirst-Lung test in a Pfizer-funded Phase II trial to test lung cancer patients under treatment with the ALK inhibitor lorlatinib (marketed as Lorbrena). Investigators hope that this will help better define resistance mechanisms …

View Post

Could All Patients With Advanced NSCLC Go Chemo-Free?

In Clinical Trials by Barbara Jacoby

By: Liam Davenport From: medscape.com Treatment with combination immunotherapy showed improved overall survival when compared with chemotherapy in patients with untreated advanced non-small cell lung cancer (NSCLC), even in the absence of programmed death ligand 1 (PD-L1) expression. This offers hope for chemotherapy-free treatment for all comers, say investigators. The new data come from the part 1 final analysis of …

View Post

Are dogs better at detecting cancer ‘than advanced technology?’

In In The News by Barbara Jacoby

By: Maria Cohut From: medicalnewstoday.com Because dogs have an extremely sensitive sense of smell, researchers are increasingly interested in finding out whether they can detect disease. One new study working with beagles has found that they can successfully “sniff out” lung cancer with extremely high accuracy. Recent data indicate that non-small cell lung cancer “is the second most common cancer” …

View Post

Checkpoint Therapeutics Announces Positive Interim Clinical Results of Anti-PD-L1 Antibody Cosibelimab

In Clinical Trials by Barbara Jacoby

Source: Checkpoint Therapeutics, Inc From: apnews.com >40% objective response rates observed in first-line non-small cell lung cancer and cutaneous squamous cell carcinoma Well-tolerated safety profile Enrollment ongoing in expansion cohorts intended to support potential BLA submissions Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with …